PBE Holdings — Invesco Biotechnology & Genome ETF
All 33 reported holdings of Invesco Biotechnology & Genome ETF (PBE) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| Invesco Private Prime Fund | 10.92% | $27.00M |
| United Therapeutics Corp. | 6.28% | $15.55M |
| Illumina, Inc. | 5.37% | $13.29M |
| Biogen Inc. | 5.05% | $12.50M |
| Incyte Corp. | 4.91% | $12.15M |
| Alnylam Pharmaceuticals, Inc. | 4.84% | $11.98M |
| Regeneron Pharmaceuticals, Inc. | 4.77% | $11.80M |
| Amgen Inc. | 4.71% | $11.65M |
| Gilead Sciences, Inc. | 4.62% | $11.42M |
| Invesco Private Government Fund | 4.20% | $10.39M |
| BioCryst Pharmaceuticals, Inc. | 3.42% | $8.46M |
| Catalyst Pharmaceuticals, Inc. | 3.30% | $8.17M |
| Arrowhead Pharmaceuticals, Inc. | 3.28% | $8.11M |
| Protagonist Therapeutics, Inc. | 3.22% | $7.96M |
| TG Therapeutics, Inc. | 3.15% | $7.78M |
| Royalty Pharma PLC | 3.13% | $7.75M |
| CareDx, Inc. | 3.07% | $7.60M |
| Neurocrine Biosciences, Inc. | 2.86% | $7.07M |
| Exelixis, Inc. | 2.80% | $6.92M |
| Bio-Techne Corp. | 2.73% | $6.75M |
| PTC Therapeutics, Inc. | 2.68% | $6.63M |
| Veracyte, Inc. | 2.62% | $6.48M |
| Acadia Pharmaceuticals Inc. | 2.59% | $6.42M |
| Vericel Corp. | 2.58% | $6.38M |
| Halozyme Therapeutics, Inc. | 2.57% | $6.36M |
| Repligen Corp. | 2.50% | $6.17M |
| Theravance Biopharma Inc. | 2.50% | $6.17M |
| Ionis Pharmaceuticals, Inc. | 2.49% | $6.15M |
| BioMarin Pharmaceutical Inc. | 2.45% | $6.05M |
| Collegium Pharmaceutical, Inc. | 2.12% | $5.25M |
| Qiagen N.V. | 2.03% | $5.01M |
| MannKind Corp. | 1.45% | $3.59M |
| Invesco Government & Agency Portfolio | 0.06% | $146.28K |